Vaccines and the Vulnerable: The Race to End Typhoid

<p>&nbsp;</p>

<p>Over the past decade, several strains (types) of <em>Salmonella typhi</em> have become resistant to multiple antibiotics. Resistant strains have been identified across the globe. However, the 2018 launch of a vaccine has slowed infections. It is estimated that TCV introduction with a catch-up campaign will avert 42.5 million cases and 506,000 deaths caused by fluoroquinolone-resistant typhoid fever, and 21.2 million cases and 342,000 deaths from multidrug-resistant typhoid fever over 10 years following introduction. This episode will cover the impact of vaccinations and the challenges to deploy effective programs.&nbsp;</p>

<p>&nbsp;</p>

<p><strong>Guests:</strong></p>

<ul>

<strong>Farah Naz Qamar </strong>-<strong> </strong>Pediatric Infectious Disease Associate Professor, The Aga Khan University, Pakistan<br>

<strong>Kathy Neuzil </strong>- Director of the Center for Vaccine Development and Global Health, University of Maryland School of Medicine<br>

<strong>Denise Garrett </strong>- Vice President, Applied Epidemiology, Sabin Vaccine Institute<br>

<strong>Calman MacLennan </strong>- Senior Program Officer, Bacterial Vaccines, Bill and Melinda Gates Foundation

</ul>

<p>&nbsp;</p>

<p>For more information on the impact of typhoid conjugate vaccines and AMR, check out CIDRAP-ASP's report,&nbsp;<a href="https://www.cidrap.umn.edu/antimicrobial-stewardship/cidrap-asp-report-vaccine-bridge">A Vaccine Is a Bridge: The New Era of Typhoid Prevention</a>.</p>